RecruitingNot ApplicableNCT05194566

Neurostimulation for the Treatment of Post-Stroke Aphasia


Sponsor

QVITI S.A.

Enrollment

64 participants

Start Date

Sep 6, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of the trial is to determine whether 75Hz transcranial alternating current stimulation (tACS) synchronized with therapeutic linguistic tasks is an effective form of therapy for post-stroke aphasia.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria9

  • Individuals with aphasia (assessed using the Boston Diagnostic Aphasia Examination) who perform the Naming Task in the range of 10%-60% accuracy will be included in the study. The overall baseline score in the Naming Task will be estimated from the two baseline measurements.
  • diagnosis of aphasia: Broca's or mixed (based on the assessment of a Speech Language Pathologist).
  • presence of a focus of injury in the left hemisphere (within one hemisphere only) as a result of the first ischemic or hemorrhagic stroke (based on CT/MRI examination);
  • chronic stage of the disease - time since the stroke occurred over 6 months.
  • ability to achieve an accuracy in the Naming Task of 10-60%.
  • -80 years
  • right-handedness before the stroke.
  • ability to give informed written consent.
  • fluency in English.

Exclusion Criteria15

  • severe cognitive, auditory or visual impairment that would preclude cognitive and language testing - inability to follow a two-step command.
  • presence of metal implants in the skull.
  • presence of major untreated or unstable psychiatric disease.
  • history of epilepsy or seizures.
  • ongoing medication that increases the risk of epileptic seizures.
  • presence in the body of cardiac stimulator, pacemaker or vagus nerve stimulator (implanted).
  • history of speech, language, hearing, or intellectual disability during childhood.
  • pregnancy (based on declarations)
  • high intolerance to stimulation.
  • occurrence of an epileptic seizure.
  • other previously absent neurological or mental symptoms
  • Withdrawal criteria:
  • high intolerance to stimulation (participants experience severe discomfort during stimulation);
  • occurrence of an epileptic seizure;
  • other previously absent neurological, physical or mental symptoms.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEtACS

Neurostimulation will be done using the Neuro Device tCS, which is a certified transcranial electrical stimulator. The device consists of a stimulator with a touch screen, two electrodes and a soft, flexible cap to ensure stability of the electrodes on the head.


Locations(2)

Think & Speak Lab at Shirley Ryan AbilityLab

Chicago, Illinois, United States

Abilities Research Center at Mount Sinai

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05194566


Related Trials